Nasdaq

CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study--Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity--Clinical trial ...

Does BMS–Foundation Medicine’s MTAP CDx Partnership Expansion Change The Bull Case For Bristol-Myers Squibb (BMY)?

In recent weeks, Foundation Medicine announced it expanded its collaboration with Bristol Myers Squibb to develop ...

The Bull Case For Guardant Health (GH) Could Change Following New ESR1 Liquid Biopsy CDx Approval – Learn Why

On 4 May 2026, Guardant Health announced that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic ...
TMCnet

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...
Business Wire

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a ...
The American Journal of Managed Care

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
Cure Today

FDA Approves Guardant360 CDx Diagnostic For Some With Colorectal Cancer

Guardant360 CDx is FDA-approved for identifying BRAF V600E-mutant mCRC patients for targeted therapy with Braftovi, Erbitux, and chemotherapy. The phase 3 BREAKWATER trial showed significant ...
Nasdaq

Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile

--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- CDX-0159 demonstrated a favorable safety ...
Motor Trend

Report: Acura CDX May Come to the U.S.

Acura began selling the CDX subcompact crossover in China last year, and now it's thinking of bringing the model to the U.S., according to a new report fromWardsAuto. The model would compete against ...